(MRNA) Moderna - Ratings and Ratios

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. Its pipeline spans respiratory vaccines, including Spikevax (COVID-19), seasonal influenza, RSV, and pandemic influenza, as well as latent vaccines targeting cytomegalovirus, Epstein-Barr virus, and HIV. The company also focuses on enteric viruses like norovirus, public health vaccines for Zika, Nipah, and Mpox, and bacterial vaccines such as Lyme disease. In oncology, Moderna develops neoantigen-based therapies and checkpoint modulators, while its rare disease portfolio includes treatments for propionic acidemia, glycogen storage disease, and phenylketonuria. Strategic collaborations include partnerships with AstraZeneca, Merck, Vertex Pharmaceuticals, and government agencies like DARPA and BARDA. Founded in 2010 and renamed in 2018, Moderna is headquartered in Cambridge, Massachusetts.

Modernas shares trade on the NASDAQ under the ticker MRNA, classified under the Biotechnology sub-industry. The company has a market capitalization of $9.95 billion, with a forward P/E ratio of 32.47 and a price-to-book ratio of 0.89. Its return on equity stands at -32.67%, reflecting significant R&D investments. The stocks average 20-day volume is 8.47 million shares, with a last price of $26.54. Technical indicators show a short-term SMA of $26.84, a mid-term SMA of $30.83, and a long-term SMA of $55.05, signaling a downtrend. The ATR of 2.00 indicates moderate volatility.